Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of REGN7075 (EGFRxCD28 Costimulatory Bispecific Antibody) in Combination With Cemiplimab in Patients With Advanced Solid Tumors

NCT04626635 is registered in ClinicalTrials.gov with Regeneron Pharmaceuticals as lead sponsor.

NCT NCT04626635
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04626635 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of REGN7075 (EGFRxCD28 Costimulatory Bispecific Antibody) in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Lead sponsor
Regeneron Pharmaceuticals
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
December 21, 2020
Completion date
March 5, 2027
Enrollment
548 (actual)
Sites
54

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors